A Phase II Trila of Sunitinib Schedule 4/2 vs. Shedule 2/1 as First Line Therapy in Metastatic Renal Cell Carcinoma.

Exclusion Criteria

• •Patients who have received any systemic therapy including targeted therapy,immunotherapy,chemotherapy etc at diagnosed.
• •Pregnant and lactating women, or female patients of child-bearing age without taking contraceptive measures
• •Patients with severe acute infection without being controlled effectively or having pyogenic and chronic infections with persistently unhealed wounds
• •Past history of serious heart diseases, including: cardiac function classification ≥NYHA class II, unstable angina pectoris, myocardial infarction, arrhythmia requiring anti-arrhythmic drug therapy (excluding β-blockers or digoxin), and uncontrolled hypertension
• •Patients with a history of HIV infection or active phase of chronic hepatitis B/C
• •negative imaging examination result 4 weeks prior to enrollment)
• •Epilepsy patients requiring drug therapy (e.g. steroids or antiepileptic drugs)
• •A history of allogeneic organ transplantation